Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $17000.0.

  • Ernexa Therapeutics' Depreciation & Amortization (CF) fell 5405.41% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $71000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $139000.0 for FY2024, which is 6547.62% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Depreciation & Amortization (CF) of $17000.0 as of Q3 2025, which was down 5405.41% from $17000.0 recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Depreciation & Amortization (CF) registered a high of $68000.0 during Q2 2022, and its lowest value of $17000.0 during Q4 2022.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $21500.0 (2023), whereas its average is $28812.5.
  • As far as peak fluctuations go, Ernexa Therapeutics' Depreciation & Amortization (CF) plummeted by 6911.76% in 2023, and later skyrocketed by 10952.38% in 2024.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Depreciation & Amortization (CF) stood at $25000.0 in 2021, then plummeted by 32.0% to $17000.0 in 2022, then rose by 29.41% to $22000.0 in 2023, then fell by 13.64% to $19000.0 in 2024, then dropped by 10.53% to $17000.0 in 2025.
  • Its last three reported values are $17000.0 in Q3 2025, $17000.0 for Q2 2025, and $18000.0 during Q1 2025.